Program
XTR004
A development code.
Its studies are mostly in Coronary Artery Disease, led by Sinotau Pharmaceutical Group.
Furthest: phase 3, since Jan 28, 20263 company-led studies, 1 open or runningNext primary completion: Jun 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sinotau Pharmaceutical Group | 31 open or running | phase 3since Jan 28, 2026 | Dec 25, 2022 | Jun 2027phase 3 · NCT07439133 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 25, 2022First study: phase 2 study in Coronary Artery DiseaseFirst studyNCT05885841 · 83 enrolled · China
- Sep 16, 2025Phase 2 study in Myocardial Perfusion ImagingNCT07187895 · 17 enrolled · China
- Jan 28, 2026Phase 3 study in Coronary Artery DiseasePhase 3 reachedNCT07439133 · 395 planned · China
Ahead
- Jun 2027Primary completion: phase 3 study in Coronary Artery DiseaseNCT07439133
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07439133Coronary Artery Disease · China | 3 | Recruiting | Jun 2027 | 395 |
| NCT07187895Myocardial Perfusion Imaging · China | 2 | Terminated | Mar 5, 2025 | 17 |
| NCT05885841Coronary Artery Disease · China | 2 | Completed | May 9, 2023 | 83 |
How it is read
Names in the registry
- “XTR004”, 3 entries
Codes read as this program: XTR004.
Conditions, from the studies’ own filings
- Coronary Artery Disease, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.